Search results
Moderna Options Trading: A Deep Dive into Market Sentiment - Moderna (NASDAQ:MRNA)
Benzinga· 6 days agoLoading... Loading... Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna MRNA ...
State’s highest paid CEO reports major drop in compensation - Boston Business Journal
The Business Journals· 3 days agoLast year, Douglas Ingram, the president and CEO of Sarepta Therapeutics (Nasdaq: SRPT), reported...
Cancer jab offers hope of a cure as NHS trials vaccines that 'destroy melanoma'
The US Sun· 3 days agoTHE world's first personalised mRNA cancer jab for melanoma is being tested in British patients. The...
Big Pharma's Blockbuster Creation Continues to Disappoint
Mercola· 5 days agoThe most recent mRNA failure was a phase 1 trial of Moderna’s mRNA human immunodeficiency virus (HIV) injection. "We are taking this very seriously," Carl Dieffenbach, head ...
A Fed meeting, jobs report, and more Big Tech earnings: What to know this week
Yahoo Finance via AOL· 14 hours ago...), Block (SQ), Booking Holdings (BKNG), Coinbase (COIN), Cigna (CI), ConocoPhillips (COP),...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 days agoAfter hitting a two-year high in February, biotech stocks have pulled back markedly in April. In...
Moderna Investors Should Beware Patent-Dispute Fallout (NASDAQ:ABUS)
Seeking Alpha· 5 days agoModerna's stock soared on positive cancer vaccine trial results, but legal troubles loom as a patent dispute threatens massive damages. Read my analysis here.
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Reuters via Yahoo Finance· 3 days agoGlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster ...
Petri Dish: Vertex scales cell manufacturing; German biotech enters Mass. - Boston Business Journal
The Business Journals· 4 days agoMoving to Massachusetts isn’t a rare move for a growing biotech, but it is newsworthy. This week saw...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 4 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...